The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.
The role of sodium and other minerals as risk factors for MS was previously unclear.
Concomitant AED and perampanel treatment was well tolerated by patients with secondarily generalized seizures.
Treatment with the biannual injection consistently resulted in greater achievement of NEDA compared to standard care.
Setting reasonable expectations can enhance patient satisfaction and improve overall treatment outcomes.
Reading and playing games may help reduce MCI risk in non-APOE-ε4 carriers.
Smoking has been linked to advanced brain atrophy in individuals with multiple sclerosis.
Researchers have uncovered a positive synergistic interaction between Alzheimer's pathology and neuropsychiatric symptoms.
Widespread misconceptions about epilepsy center services prevent many patients from getting the care they need and deserve.
Personal health records have the potential to empower patients as they transition from hospital to home.
Children with autism are known to have increased rates of epilepsy; however, many prior studies aimed to quantify these rates are small.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
While Botox is approved by the US FDA for the treatment of poststroke upper limb spasticity, its efficacy in poststroke lower limb spasticity is still being investigated.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Lipoic acid, an easily available and inexpensive oral antioxidant acid, has been proposed as a therapeutic approach in multiple sclerosis.
The findings should help reassure both patients and clinicians during the family planning process.
Responsive Stimulation May Be Viable Treatment for Medically Intractable Mesial Temporal Lobe EpilepsyApril 18, 2016
While temporal lobectomy is the best treatment for many with medically intractable MTLE, responsive stimulation provides a treatment alternative..
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
Glucocerebrosidase gene mutation has been found to be strongly associated with REM sleep behavior disorder.
Investigators aimed to quantify functional connectivity differences in patients with MS and to determine the association between these alterations and cognitive performance.
An altered functional network involving the ipsilateral and contralateral hippocampal areas was associated with cognitive impairment in patients with temporal lobe epilepsy.
A nurse-driven stroke evaluation algorithm improved patient triage and treatment utilization.
Elevated levels of CMPF, which has been linked to beta cell dysfunction in diabetes and thyroid disorders, have been identified in patients with MS.
Adaptive programs allow for real-time adjustment to a user's level of performance.
Effective shared decision making promotes collaboration among the care team and can improve patient outcomes.
Phase 2 results show anti-CGRP receptor monoclonal antibody effective for the prevention of episodic migraine.
Investigators aimed to predict outcomes in patients with mild traumatic brain injury by identifying MRI features that are associated with clinical symptoms.
Researchers hypothesized that an altered balance of sex hormones in men with gender identity disorder would increase the risk of MS.
As ICH volume is known to increase within the first 3 hours following intracerebral hemorrhage, timely reversal is vital for patients on anticoagulation.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Psychological Therapies May Help Older Adults With Chronic Pain
- Concussion Misdiagnosis Associated With Emergency Department Stay, Injury Type
- Vitamin D: The Only Dietary Supplement Showing Significant Benefit for MS
- Evolution of NEDA: Q&A With Cleveland Clinic's Dr Robert Bermel
- Micronutrient Levels May Be Altered in ADHD
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- FDA Approves Aimovig for Migraine Prevention
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Unmet Therapy Needs Common in Children With Traumatic Brain Injury
- Congenital Heart Disease, Hispanic Ethnicity Associated With Increased Mortality in Pediatric Arterial Ischemic Stroke
- Addressing Migraine That Mimics Stroke
- Antidepressant Use for Insomnia: Is It Effective?
- Peripheral Neuropathy Common in Childhood Cancer Survivors